It comes as part of a larger move by the Cambridge, Massachusetts-based company to finally get its shots authorized for people under 18 in America - putting it on par with its main competition in the rollout of the shots, Pfizer.

Some experts doubt that the shots are needed at all in children, though, especially for those as young as six months old who face little individual risk from the virus.

Recent data revealed by the Centers for Disease Control and Prevention (CDC) this week found that nearly three of every four minors in America have been infected with the virus, though they make up 0.1 percent of virus deaths in the country.

'There is an important unmet medical need here with these youngest kids,' Dr. Paul Burton, Moderna's chief medical officer, said in a statement.

'Two kid-size shots 'will safely protect them. I think it is likely that over time they will need additional doses. But we're working on that.'

As of now, U.S. children aged five and older are eligible for the COVID-19 vaccine, though only Pfizer's shot has received authorization. The Pfizer jab is also available as a booster for children 12 and older.

The conversation over whether to vaccinate children under the age of five is slowly loudening.

On one side, many parents and even officials at leading regulatory bodies like the FDA and CDC are clamoring to have the shots approved in young children, in a bid to extinguish even the slight risk presented to them by the virus.